SCHEMBL3424550

SCHEMBL3424550

O=C1NCCC(=O)c2c1[nH]c(Br)c2Br

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 9/20 0.55
CDK5R1 Q15078 9/20 0.55
CCNB2 O95067 6/20 0.55
CDK1 P06493 6/20 0.55
CCNB1 P14635 6/20 0.55
CCNB3 Q8WWL7 6/20 0.55
CDK4 P11802 3/20 0.55
ERBB2 P04626 2/20 0.55
CHEK1 O14757 2/20 0.55
MAP2K1 Q02750 5/20 0.49
RAF1 P04049 4/20 0.49
MAPK1 P28482 4/20 0.49
PARP16 Q8N5Y8 1/20 0.40
PARP3 Q9Y6F1 1/20 0.40
TUBB4A P04350 1/20 0.36
TUBB P07437 1/20 0.36
TUBA3C P0DPH7 1/20 0.36
TUBA1B P68363 1/20 0.36
TUBA4A P68366 1/20 0.36
TUBB4B P68371 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Spongiacidin A SCHEMBL23938900 0.72 CDK5 (0.56) CDK5CDK5R1CCNB2CDK1CCNB1
SCHEMBL3426241 0.70 CCNB2 (0.54) CDK5CDK5R1CCNB2CDK1CCNB1
SCHEMBL7845370 0.70 CDK5 (0.55) CDK5CDK5R1CCNB2CDK1CCNB1
SCHEMBL15426067 0.70 CDK5 (0.73) CDK5CDK5R1CCNB2CDK1CCNB1
SCHEMBL3001277 0.68 MAPT (0.52) CDK5CDK5R1CCNB2CDK1CCNB1
SCHEMBL13341120 0.68 CDK5 (0.67) CDK5CDK5R1CCNB2CDK1CCNB1
SCHEMBL3424813 0.68 CDK5 (0.67) CDK5CDK5R1CCNB2CDK1CCNB1
SCHEMBL3424811 0.68 CDK5 (0.67) CDK5CDK5R1CCNB2CDK1CCNB1
SCHEMBL3427648 0.67 TUBB4A (0.68) CHEK1MAP2K1RAF1MAPK1TUBB4A
SCHEMBL7837428 0.66 MAP2K1 (1.00) CDK5CDK5R1CCNB2CDK1CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7713958-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2010-05-11 US disclosed
US-20090137555-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2009-05-28 US disclosed
US-7423031-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2008-09-09 US disclosed
US-20050153955-A1 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2005-07-14 US disclosed
WO-2004098520-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2004-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153955-A1 Compounds and compositions as protein kinase inhibitors CDK1, CDK3, CDK11A CDK5 16/4885CDK5R1 38/4885CCNB2 59/4885
US-20090137555-A1 Compounds and Compositions as Protein Kinase Inhibitors CDK1, CDK3, CDK2 CDK5 14/4885CDK5R1 37/4885CCNB2 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.